Ideal patient for Venetoclax/Obinutuzumab combination | Dr. Jeff Sharman | Oncology Brothers

In discussion with Dr. Jeff Sharman, about how to treat CLL. Chronic lymphocytic leukemia course has changed since we have started using BTK inhibitors. Dr. Sharman, director of hematology research at US Oncology Network and Director of Research at Willamette Valley Cancer Institute, was the first to ever give this medication here in the US. We discuss important nuances of CLL management with him, when to proceed with observation vs. treatment, when treating what BTKi to utilize, important side effects one has to keep in mind, and much more.
#treatment #algorithm #CLL #venetoclax #2023 #cancer #oncology #oncbrothers
Website: www.oncbrothers...
Twitter:
/ oncbrothers
Contact us at [e-mail]